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Abstract 
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease 
characterized by the loss of upper cortical and lower motor neurons. ALS causes death 
within 2-5 years of diagnosis. Diet and body mass index influence the clinical course of 
disease, however there is limited information about the expression of metabolic proteins and 
fat-derived cytokines (adipokines) in ALS. In healthy controls and subjects with ALS, we have 
measured levels of proteins and adipokines that influence metabolism. We find altered levels 
of active ghrelin, gastric inhibitory peptide (GIP), pancreatic polypeptide (PP), lipocalin-2, 
plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6) and 8 (IL-8), and tumor necrosis 
factor alpha (TNF) in the plasma of ALS patients relative to controls. We also observe a 
positive correlation between the expression of plasma nerve growth factor (NGF) relative to 
disease duration, and an inverse correlation between plasma glucagon and the ALS 
functional rating scale-revised (ALSFRS-R). Further studies are required to determine 
whether altered expression of metabolic proteins and adipokines contribute to motor neuron 
vulnerability and how these factors act to modify the course of disease. 
 
Keywords: Amyotrophic lateral sclerosis, metabolism, body mass index, adipose, 
adipokines, neurodegeneration
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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is characterized by 
the irreversible loss of upper cortical and lower motor neurons. ALS causes death within 2-5 
years of diagnosis, generally due to respiratory failure [1]. The primary cause for ALS 
remains unknown, but abnormal function and folding of proteins and abnormal RNA 
processing [2-6], excitotoxicity [7] , mitochondrial dysfunction [8],  and astrocyte- [9] and 
microglial [10] toxicity are reported to contribute to disease. Mutations in causative genes 
(e.g. SOD1 and TDP-43) are associated with familial ALS, but have also been observed in 
ALS cases with no known or obvious family history [11]. 
 
In the absence of curative therapies in ALS, it is important to identify factors that 
modify the progression of disease. Metabolic abnormalities have been described in ALS. 
These include hypermetabolism, which is observed in both familial and sporadic ALS 
patients [12,13], decreased nutritional intake [14], and weight loss resulting in a decline in 
body mass index (BMI) [15]. The impact of altered metabolic balance on the course of 
disease is demonstrated by the finding that correcting for hypermetabolism improves survival 
in mouse models of ALS [16] and that dietary supplementation of ALS patients provides 
some benefit, possibly by maintaining body weight [17]. Indeed, ALS patients with a BMI 
between 30 and 35 have better survival outcome [18], and a faster rate of reduction in BMI 
throughout the course of ALS is highly correlated with accelerated disease progression [15]. 
 
Whole body metabolism is regulated by a network of proteins and peptides. Given the 
evidence of metabolic abnormalities in ALS, this study aimed to determine whether ALS 
patients and age-matched healthy subjects differ in levels of metabolic proteins and 
adipokines that are involved in regulating metabolic homeostasis (targets assessed in this 
study are listed in Supplementary Table 1). This study also aimed to assess whether levels 
of these proteins and adipokines are associated with BMI, disease duration, and functional 
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capacity (determined by the ALS functional rating scale-revised; ALSFRS-R) [19] of subjects 
with ALS. 
 
2. Materials and Methods 
2.1 Study population 
Ethical approval for the study was obtained from the Royal Brisbane and Women’s Hospital 
(RBWH), The Wesley Hospital, and The University of Queensland ethics committees. The 
study was conducted in accordance with the principles set out in the Declaration of Helsinki. 
We enrolled 68 ALS patients (30.9% female, 69.1% male) from the RBWH Motor Neuron 
Disease clinic between March 2010 and March 2014. For healthy controls, we enrolled 34 
age-matched healthy volunteers from the RBWH, The Wesley Hospital, and The University 
of Queensland. Control subjects were not suffering from any disease condition and were not 
genetically related to the ALS patients recruited into this study. ALS patients had clinically 
definite or probable ALS (10.3% familial. 89.7% sporadic) according to the revised El 
Escorial criteria [20]. The clinical details of the patients are listed in Table 1. To be included 
in the study, patients were required to have onset of disease in the limbs. Patients with 
bulbar onset were excluded due to swallowing problems associated with bulbar symptoms. 
There was no significant difference between controls and ALS subjects in age or BMI. The 
functional status of ALS patients was evaluated using the ALSFRS-R [19]. All patients 
provided consent to participate in the study. 
 
2.2 Plasma Collection 
Blood samples were collected between 1000hrs and 1430hrs into 4 mL BD Vacutainers® 
containing 1267.2 mg of the anti-coagulant K2EDTA (BD, Franklin Lakes, NJ, USA). Samples 
were centrifuged for 3 minutes at 3600rpm. Plasma was collected, frozen on dry ice, and 
stored at -80ºC for further analysis. The duration of disease from onset of symptoms to the 
date of collection was recorded.   
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2.3 Multiplex Assays 
Plasma samples were treated with a protease inhibitor cocktail (Millipore, MA, USA; mM: 200 
AEBSF, 0.16 bovine aprotinin, 10 bestatin, 3 E-64 protease inhibitor, 4 Leupeptin, 2 
Pepstatin A), dipeptidyl peptidase 4 (DPP-IV; Millipore; 50mM), and aprotinin (Sigma, MO, 
USA; 200mg/ml) and phenylmethanesulfonylfluoride (PMSF; Sigma; 0.1mg/ml). Magnetic 
multiplex assays were performed according to the manufacturer’s instructions (Millipore). 
Targets on the human metabolic hormone assay (HMHMAG-34K) were: total amylin, c-
peptide, GIP, ghrelin (active), glucagon, glucagon-like peptide-1 (GLP-1, active), PP and 
peptide YY (PYY). Targets on the human adipokine assays (HADK1MAG-61K and 
HADK2MAG-61K) were: adiponectin, hepatocyte growth factor (HGF), insulin, IL-6, IL-8, 
leptin, lipocalin-2, monocyte chemoattractant protein-1 (MCP-1), NGF, total PAI-1, resistin, 
and TNF. The origin and biological function of these targets are summarized in 
Supplementary Table 1.  
 
2.4 Statistical analysis 
Data were analyzed using Prism 6.0c (Graphpad Software Inc., CA, USA). Normality of 
residuals (distribution) within control or ALS groups for all measures were assessed by 
Shapiro-Wilk W test. Differences between groups were determined by Mann-Whitney U test. 
The strength of associations between metabolic proteins and adipokines and BMI, ALSFRS-
R scores and disease duration was determined by Spearman's rank correlation coefficient 
analysis. Data in tables are presented as mean ± SD. A P value of less than 0.05 denotes 
statistical significance. 
 
3. Results 
3.1 Expression of metabolic proteins and adipokines in ALS patients and controls 
The expression of human metabolic proteins and adipokines in ALS patients and controls is 
presented in Table 2. For metabolic proteins, there was no difference in levels of total amylin, 
c-peptide, active GLP-1, glucagon, insulin, and PYY between controls and ALS patients. The 
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plasma concentration of active ghrelin, GIP and PP was significantly lower in ALS patients 
than controls. For adipokines, there was no difference in levels of HGF, leptin, MCP-1, NGF, 
and resistin between controls and ALS patients. Circulating levels of adiponectin, IL-6, IL-8, 
lipocalin-2, PAI-1, and TNF were significantly higher in ALS patients than in controls. 
Riluzole had no effect on the expression of any of the metabolic proteins and adipokines. 
Of the factors that showed significant differences between ALS subjects and controls, 
ghrelin, adiponectin, IL-6, IL-8 and TNF were differentially affected by gender within the 
ALS cohort (Supplementary Table 2). Ghrelin, which was reduced in the ALS group, was 
significantly lower in female ALS subjects. Adiponectin, which was higher in ALS subjects, 
was higher in female ALS subjects. IL6, IL8 and TNF, which were higher in ALS subjects, 
were lower in female ALS subjects.  
 
3.2 Correlation analysis of plasma metabolic proteins and adipokines with clinical features 
3.2.1 Correlation of plasma metabolic proteins and adipokines with BMI 
Of the 34 healthy subjects and 68 ALS patients, measures of BMI were available from 25 
and 46 persons respectively. Supplementary Table 3 summarizes Spearman correlation 
analyses and comparison of fit for metabolic proteins and adipokines relative to BMI in 
controls and ALS patients. BMI was significantly correlated with levels of leptin, PAI-1, and 
MCP-1 in the controls (Figure 1A-C). For the ALS cohort, we observed significant positive 
correlation of plasma insulin, c-peptide and leptin with BMI (Figure 1A, 1D and 1E). Plasma 
adiponectin showed a significant inverse correlation with BMI in ALS (Figure 1F). We found 
no correlation between BMI and ALSFRS-R (Figure 1G) or BMI and disease duration (Figure 
1H).  
 
3.2.2 Correlation of plasma metabolic proteins and adipokines with ALSFRS-R and disease 
duration 
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The correlation between levels of metabolic proteins and adipokines with ALSFRS-R scores 
and disease duration are shown in Supplementary Table 4. There was a significant inverse 
correlation between the expression of circulating levels of glucagon and ALSFRS-R in ALS 
patients (Figure 1I). There was a significant positive correlation between circulating levels of 
NGF and disease duration in ALS patients (Figure 1J). 
 
4. Discussion 
We present data showing differing levels of metabolic proteins and adipokines between ALS 
patients and healthy controls. The potential metabolic consequences of our findings specific 
to ALS are discussed below and are listed in Table 3. 
 
We found lower circulating levels of ghrelin, GIP and PP in ALS patients. Ghrelin is 
an appetite stimulating hormone [21], so low levels of ghrelin may contribute to reduced total 
food intake, and consequently malnutrition and reduced survival in ALS [22]. Indeed, ghrelin 
administration promotes food intake and prolongs survival in a mouse model of ALS [23]. 
Consistent with reduced food intake in ALS, we observe lower levels of GIP and PP in ALS 
patients. GIP stimulates insulin secretion in response to food intake [24], whereas PP 
mediates peripheral insulin action [25]. Reduced levels of GIP and PP in our ALS cohort may 
provide a mechanism for the diminished peripheral insulin action and glucose intolerance 
observed in ALS [26].  
 
We observed increased expression of a number of adipokines that are linked to 
metabolic disease. Adiponectin regulates glucose and fatty acid oxidation [27], chronic 
elevation of IL-6 promotes hepatic insulin resistance [28] while acute elevation of IL-6 
promotes the supply of glucose and fat to skeletal muscle [29]. IL-8 is correlated with insulin 
resistance in obesity and metabolic syndrome [30,31] while PAI-1 is associated increased 
visceral fat mass [32] and insulin resistance in lean individuals [33]. Lipocalin-2 is associated 
with increased total energy expenditure and increased fat oxidation [34], and TNF induces 
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lipolysis [27]. Therefore, the increased expression of adiponectin, IL-6, IL-8, lipocalin-2, PAI-1 
and TNFa that we observe in ALS may contribute to the reported occurrence of glucose 
intolerance and insulin resistance [26,35], hypermetabolism [12,13] and the loss of fat mass 
[18] that is seen in ALS. Nonetheless, the mechanism for the increase in the expression of 
these adipokines might also be inherent to pathologies associated with ALS. Indeed, it is 
possible that IL-6, IL-8, and TNF originate from the activation of innate immunity [36] and 
primed astrocytes [37], while lipocalin-2 may originate from activated microglia [38].  
 
Consistent with observations that leptin is secreted proportionate to fat mass [39], 
BMI was positively correlated with circulating measures of leptin in the control and ALS 
cohorts. Since levels of PAI-1 [40] and MCP-1 [31] are positively associated with BMI, the 
correlation between levels of PAI-1 and MCP-1 with BMI in our control cohort is to be 
expected. In contrast, we observed no association between PAI-1 or MCP-1 with BMI in our 
ALS cohort. PAI-1 and MCP-1 are associated with changes in the distribution of or mass of 
visceral fat [32,41]. Therefore, the increased visceral fat mass and the increased ratio of 
visceral to subcutaneous fat that is seen in ALS [42] might underlie the greater variability in 
circulating levels of PAI-1 and MCP-1 and consequently the lack of association between PAI-
1 and MCP-1 and BMI in the ALS cohort. 
 
Insulin and c-peptide are associated with increased adiposity and BMI. Thus, the 
relationship between insulin and BMI in subgroup of control and ALS subjects that were BMI-
matched, and the lack of deviation in this relationship between the two cohorts is to be 
expected. As c-peptide is co-secreted with insulin, our observations that BMI correlated with 
c-peptide levels in the ALS cohort mirror the positive correlation between insulin and BMI. 
 
While adiponectin is inversely associated with fat mass [43], the lack of relationship 
between circulating levels of adiponectin and BMI are in line with observations that BMI does 
not independently affect plasma adiponectin levels in healthy lean and obese individuals [44]. 
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The majority of our control and ALS patients fell within the healthy to overweight BMI range, 
yet we observed a negative association between adiponectin and BMI in ALS patients. Since 
adiponectin levels are correlated with the development of metabolic complications of 
adiposity [45], our data support previous observations of increased central obesity [42] and 
insulin resistance [35] in ALS. 
 
We found that lower levels of circulating glucagon were associated with higher 
ALSFRS-R scores. This suggests that an increase in disease severity in ALS patients is 
correlated with increased circulating glucagon levels. Indeed, given that impaired glucose 
homeostasis in ALS could occur as a consequence of higher levels of circulating glucagon 
[46], our data is congruent with observations that insulin resistance is related to disease 
severity and outcome in ALS [47].  
 
In our ALS patients, NGF levels correlated with disease duration. This may be related 
to increased fat mass, as is seen in obesity and metabolic syndrome [48]. As we observed 
no relationship between BMI and disease duration in our ALS cohort, it seems unlikely that 
the association of NGF with disease duration is linked with metabolic derangements 
associated with fat mass. Rather, increased NGF in patients with longer disease duration 
may underlie reduced food intake, since NGF suppresses food intake [49]. Alternatively, the 
increase in circulating NGF in our ALS cohort may arise from increased expression of NGF in 
skeletal muscle [50] or altered astrocyte-motoneuron cross-talk [51]. This was not directly 
assessed in this study. 
 
While the ALS subjects in this study were typical of a clinical population in that 
approximately 10% had familial ALS, we excluded patients with bulbar onset disease to 
remove any metabolic disturbance that might occur from malnutrition due to an inability to 
eat. Although the patients were studied at the same time of day, we did not control for food 
intake. Meal patterning influences the majority of metabolic proteins. Although we observed 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 10 
clear and consistent differences between ALS patients and healthy controls, our data need to 
be confirmed in a study that strictly controls for food intake, and that is extended to patients 
with bulbar onset disease. 
 
Under normal physiological conditions, the expression of metabolic proteins and 
adipokines varies relative to BMI and age. Given that BMI values were only matched for a 
subset of our control and ALS populations, we cannot exclude that the altered expression of 
metabolic proteins and adipokines observed in this study might be related to BMI. However,  
in contrast to previous reports [16,21,47], we found no correlation between BMI and disease 
severity or disease duration in our ALS patients with known BMI. Given that our measures do 
not account for the progressive weight loss that is seen in ALS patients during disease 
progression, long-term serial assessment of the relationship between BMI and ALSFRS-R or 
disease duration is also needed to assess associations between BMI and disease severity, 
and BMI and disease progression.  
 
Gender impacts the prevalence and severity of ALS [52], and thus gender-effects 
may contribute to the differential expression of metabolic proteins and adipokines between 
ALS patients and controls. Levels of amylin, ghrelin, adiponectin, HGF, IL-6, IL-8, resistin 
and TNF differed between male and female ALS patients. Of these, amylin, ghrelin, HGF, 
and IL-8 levels varied from anticipated gender specific differences that would normally be 
observed [53-56]. How differential expression of these factors may impact disease 
prevalence, severity and possibly progression remains completely unexplored. 
 
Finally, while metabolic abnormalities have been described in familial and sporadic 
cases of ALS [12,13], it is possible that the heterogeneity of ALS may lead to varying 
degrees of metabolic dysfunction between patients with different ALS genotypes and 
phenotypes. Thus, there is a need for studying metabolic disturbances across the whole 
spectrum of ALS. 
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In summary, we observe a number of alterations in the expression of metabolic 
proteins and adipokines between ALS patients and BMI matched controls. These data, in 
combination with current clinical observations of the impact of altered metabolic balance in 
ALS, provide evidence to substantiate the existence of metabolic responses in ALS, and 
shed light on altered homeostatic processes in this complex disease. Future studies are 
needed to determine whether altered expression of metabolic proteins and adipokines 
contribute to motor neuron vulnerability, or whether/how these factors act to modify the 
course of disease. 
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Figure Legends 
Figure 1: Correlation analysis of plasma metabolic proteins and adipokines in healthy 
controls and patients with amyotrophic lateral sclerosis. (A) BMI correlated with levels of 
leptin, (B) plasminogen activator inhibitor 1 (PAI-1), and (C) monocyte chemoattractant 
protein-1 (MCP-1) in the controls. For the ALS cohort, plasma levels of (A) leptin, (D) insulin, 
and (E) c-peptide increased relative to an increase in BMI. (F) Plasma adiponectin was 
inversely correlated with BMI in the ALS cohort. (G) Measures of BMI in ALS patients did not 
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correlate with ALSFRS-R. (H) The inverse relationship between BMI and disease duration 
did not reach significance. (I) A significant inverse correlation exists between circulating 
levels of glucagon and ALSFRS-R, and (J) a positive correlation exists between circulating 
levels of NGF and disease duration. 
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Figure 1 
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Highlights 
 
1. ALS patients have altered levels of metabolic proteins and adipokines relative to 
controls. 
2. There is a positive correlation between the expression of plasma nerve growth factor 
relative to disease duration. 
3. There is an inverse correlation between plasma glucagon and ALSFRS-R. 
